Upstream Bio, Inc. (UPB)
2.74
-0.25
(-8.36%)
USD |
NASDAQ |
Oct 23, 16:00
2.735
0.00 (0.00%)
After-Hours: 20:00
Upstream Bio Enterprise Value : -110.28M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -110.28M |
| October 22, 2026 | -96.59M |
| October 21, 2026 | -106.99M |
| October 20, 2026 | -105.90M |
| October 19, 2026 | -106.99M |
| October 16, 2026 | -109.18M |
| October 15, 2026 | -75.77M |
| October 14, 2026 | -73.04M |
| October 13, 2026 | -65.92M |
| October 12, 2026 | -31.96M |
| October 09, 2026 | -2.929M |
| October 08, 2026 | -11.14M |
| October 07, 2026 | -7.859M |
| October 06, 2026 | -8.954M |
| October 05, 2026 | 5.286M |
| October 02, 2026 | 15.69M |
| October 01, 2026 | 15.69M |
| September 30, 2026 | 28.29M |
| September 29, 2026 | 23.91M |
| September 28, 2026 | 29.93M |
| September 25, 2026 | 33.22M |
| September 24, 2026 | 22.81M |
| September 23, 2026 | 23.91M |
| September 22, 2026 | 40.34M |
| September 21, 2026 | 33.49M |
| Date | Value |
|---|---|
| September 18, 2026 | 32.12M |
| September 17, 2026 | 30.48M |
| September 16, 2026 | 31.58M |
| September 15, 2026 | 39.79M |
| September 14, 2026 | 57.87M |
| September 11, 2026 | 53.48M |
| September 10, 2026 | 54.58M |
| September 09, 2026 | 66.08M |
| September 08, 2026 | 78.68M |
| September 04, 2026 | 68.82M |
| September 03, 2026 | 72.65M |
| September 02, 2026 | 94.56M |
| September 01, 2026 | 98.40M |
| August 31, 2026 | 102.23M |
| August 28, 2026 | 106.06M |
| August 27, 2026 | 111.54M |
| August 26, 2026 | 130.16M |
| August 25, 2026 | 132.90M |
| August 24, 2026 | 101.68M |
| August 21, 2026 | 121.40M |
| August 20, 2026 | 114.83M |
| August 19, 2026 | 151.25M |
| August 18, 2026 | 114.83M |
| August 17, 2026 | 130.71M |
| August 14, 2026 | 126.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sutro Biopharma, Inc. | 240.16M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.70M |
| Revenue (Quarterly) | 0.773M |
| Total Expenses (Quarterly) | 40.48M |
| EPS Diluted (Quarterly) | -0.7276 |
| Gross Profit Margin (Quarterly) | 93.53% |
| Profit Margin (Quarterly) | -5.14K% |
| Earnings Yield | -105.3% |
| Normalized Earnings Yield | -105.23 |